Replies to post #50322 on PharmaCyte Biotech Inc (PMCB)

[frosr6]

Pmcb sinking fast! Concerning?? I'd say so for investors who were suckered by pmcb and their affiliates. Pmcb needs to be valued at $75m+ by NON AFFILIATED share holders. Only way that happens is the stock more than doubles. LMAO

If We Become Ineligible To Make Offerings Under Our Registration Statement on Form S-3, Our Ability To Raise, And The Cost Of Raising, Capital May Be Adversely Affected.

If the aggregate market value of our common stock held by non-affiliates of the Company declines below $75 million as of the date of filing of our Annual Report on Form 10-K for the fiscal year ended April 30, 2016, we will become ineligible to make offerings under our effective Form S-3 registration statement until no earlier than the time that such aggregate market value reaches $75 million, at which time we may become eligible again to make offerings under Form S-3. In that event, if it becomes necessary to raise additional capital, we would be required to engage in a private sale of securities or a public offering under Form S-1. We cannot assure you that any such financing will be available as needed or if available, on terms favorable to us, and may result in higher costs of capital to the Company and higher transaction expenses. Additionally, any such future financing may be dilutive to stockholders’ present ownership levels and such additional securities may have rights, preferences, or privileges that are senior to those of our existing common stock.

[mick]

http://www.barchart.com/interactive_charts/stocks/pmcb

[frosr6]

$not PMCB
A breakthrough that could cure diseases from cancer to diabetes has been discovered by US doctors

August 18, 2016
Breakthrough in bone marrow transplants could be the answer, scientists say.

CALIFORNIA, United States, Wednesday August 17, 2016 – The treatment of some of mankind’s greatest killers could be revolutionized by a breakthrough in bone marrow transplants.

Scientists from Stanford University have made the life-saving infusions so safe that they say they could be used to treat numerous conditions and could provide a life-long cure with a single treatment.

The new technique could be the “Holy Grail” of transplantation, ushering in “a whole new era in disease treatment,” according to the scientists.

Critically ill patients with leukemia and other blood cancers are currently given chemotherapy or radiotherapy to wipe out their own diseased cells, before being given an infusion of healthy marrow.

The existing procedures nevertheless come with a host of side-effects and up to 20 percent of patients die from complications.

Since many of the problems are caused by the chemo or radiotherapy, the researchers went in search of a safer way of eliminating the cells.

They found it by using two different antibodies to trick the body into attacking the diseased marrow and destroying it.

Using this method in experiments in mice, more than 99 percent of the bone marrow cells were eliminated, according to a report in the journal Science Translational Medicine.

The Stanford researchers said: “If it works in humans like it did in mice, we would expect the risk of death would drop from 20 percent to effectively zero.”

The researchers also devised a way of purifying the donated bone marrow, to make the transplant even safer.

According to study co-author Irving Weissmann: “There is almost no category of disease or organ transplant that is not impacted by this research.

“If and when this is accomplished, it will be a whole new era in disease treatment and regenerative medicine.”

The bone marrow is the body’s blood cell “factory” so transplants are usually used to treat blood cancers at present.

But the marrow also makes most of the cells in the body’s immune system, so any disease caused by a rogue immune response could potentially be cured by a one-off transplant.

Childhood diabetes, multiple sclerosis, rheumatoid arthritis and other autoimmune diseases could reportedly be in the treatment’s grasp, and the technology is also said to have the potential to make heart, lung and other organ transplants safer.

http://www.caribbean360.com/news/breakthrough-cure-diseases-cancer-diabetes#ixzz4Hgg2brVR

[frosr6]

Another threat to pmcb?? Uh Oh!

New cancer nanomedicine reduces pancreatic tumour growth

New cancer nanomedicine reduces pancreatic tumour growth
Nanoparticles. Credit: Thinkstock
Australian cancer researchers have developed a highly promising nanomedicine that could improve treatment for pancreatic cancer – the most deadly cancer in Australia.


Australian cancer researchers have developed a highly promising technology to deliver gene-silencing drugs to treat pancreatic cancer – the most chemo-resistant and deadly cancer in Australia.

When tested in mice, the new nanomedicine resulted in a 50 per cent reduction in the growth of tumours and reduced the spread of pancreatic cancer.

The UNSW-led research, published in the Biomacromolecules journal, provides new hope for pancreatic cancer patients, most of whom succumb to the disease within three to six months of diagnosis.

Lead researcher Dr Phoebe Phillips, from UNSW's Lowy Cancer Research Centre, said it was devastating for her clinical colleagues when they had to tell pancreatic cancer patients that the best chemotherapy drug available could prolong life by only 16 weeks.

"A major reason for the lack of response to chemotherapy is that pancreatic tumours have an extensive scar tissue which makes up to 90 per cent of the tumour," Dr Phillips said.

"This scar causes pancreatic cancer cell chemotherapy resistance and is a physical barrier to chemotherapy drug delivery to tumours.

"We recently identified a key promoter of tumour growth, cancer spread and chemo-resistance in pancreatic tumours called ßIII-tubulin. Inhibition of this gene resulted in a 50 per cent reduction in tumour growth and reduced the spread of the cancer in mice," Dr Phillips said.

The problem with therapeutically targeting this gene is that it is difficult to deliver drugs to it. To overcome this problem, the researchers have developed a nanomedicine which consists of a state-of-the-art nanoparticle that can package small RNA molecules (DNA photocopies of cells) and greatly inhibit ßIII-tubulin.

The researchers have shown that their novel nanoparticle can deliver therapeutic doses of small RNAs to pancreatic tumours in mice, despite the presence of scar tissue, and successfully inhibit ßIII-tubulin.

"The significance of our nanomedicine technology lies in its potential to inhibit any tumour-promoting gene or a cocktail of genes personalised to the genetic profile of a patient's tumour," Dr Phillips said.

"This work has the potential to develop new therapies to target this drug-resistant cancer and improve the effectiveness of current chemotherapies, which may increase survival and quality of life for pancreatic cancer patients."